-
$250 million (USD) plant will help produce transformational cell and gene therapies on a global scale
-
Creating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply for late-stage clinical trials
-
New plant helps break industry-wide bottleneck in manufacturing capacity for regenerative medicines
-
100,000 sq. ft. building advances Bayer’s sustainability efforts – first fully electric manufacturing plant in Bayer’s global pharmaceutical manufacturing network
Definition of the Regenerative Medicine Industry?
The Regenerative Medicine (RM) Industry is a rapidly growing market with more than 1,550+ companies worldwide developing products for therapeutic for use in humans. As with any growing industry, the question becomes, how do you define the Regenerative Medicine Industry?
To answer this question, it is important to look at the key components that compose the human body, which are:
- Genes
- Cells
- Tissues
- Organs
Novo Nordisk Sinks US $136M into Landmark Stem Cell Manufacturing Facility in Denmark
The Novo Nordisk Foundation will invest up to US$136 million in a new cell therapy manufacturing facility in Lyngby, Denmark.
The Novo Nordisk Foundation is making a substantial commitment of up to DKK 950 million (US $136M) to create an advanced facility dedicated to scaling up cell therapies for use in human patients. This facility, known as the Novo Nordisk Foundation Cellerator, is poised to address a critical gap in the Danish cell therapy ecosystem. Its overarching goal is to facilitate the transition from groundbreaking cell therapy research to tangible treatments for individuals grappling with various chronic diseases such as chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes, and several forms of cancer. [Read more…]
Types of CAR-T Cells: Improvements in CAR Design and Construction
What are the types of CAR-T cells and how have they changed in recent years? CAR-T cells are immune cells that are artificially engineered to express a particular chimeric antigen receptor (CAR), which have shown great potential in killing cancer cells. Chimeric antigen receptors (CARs) are artificially produced recombinant receptors having both antigen-binding and T-cell activating potentials.
CARs are composed of an extracellular recognition domain sourced from monoclonal antibodies (mAbs) and an intracellular signaling domain including CD3- and costimulatory domains for triggering endogenous signaling pathways of T-cells. [Read more…]
Danaher’s Ventures Pours $18M into BlueWhale Bio, a Cell Therapy Manufacturing Company Co-founded by Carl June
-
BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania
-
BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost
-
Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace, Hillhouse Capital
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 47
- Next Page »